Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer

AUAUniversity

Контент предоставлен AUAUniversity and American Urological Association. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией AUAUniversity and American Urological Association или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.

6M ago 34:00

MP3•Главная эпизода

The AUA Expert Exchange Podcast: Discussions in Managing GU Cancer: Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer CME Available: https://auau.auanet.org/node/39542 Release Date: December, 2023 Expiration Date: December, 2024 LEARNING OBJECTIVES: At the conclusion of this activity, participants will be able to: 1. Identify the rationale behind using adjuvant therapies in high-risk non-metastatic kidney cancer and the goals of adjuvant treatment. 2. Describe the adjuvant therapies that have been investigated to date for high-risk non-metastatic kidney cancer, including targeted therapies, immunotherapies, and combination approaches. 3. Discuss the challenges and limitations associated with adjuvant therapy trials in high-risk non-metastatic kidney cancer, such as patient selection, trial design, and long-term follow-up. ACKNOWLEDGEMENTS: Support provided by independent educational grants from: AstraZeneca Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Lantheus Medical Imaging Merck & Co., Inc.

342 эпизодов

#Prostate Cancer #Men's Health #AUAUniversity #Health and Well-Being #Podcasting Education #American Urological Association